Article Sidebar
Views pdf: 88
TREATMENT RESULTS OF FIRST-LINE PEMBROLIZUMAB FOR STAGE IV NON-SMALL CELL LUNG CANCER PD-L1 ≥1% IN K HOSPITAL
Main Article Content
Abstract
Objectives: Assessing the treatment results and adverse events of first-line pembrolizumab for the treatment of stage IV non -small cell lung cancer patients in K hospital from 01/2024 to 04/2025. Patients and methods: Descriptive study of 40 patients diagnosed of stage IV NSCLC at K hospital from 01/2024 to 04/2025. Results: The partial response rate is 55%, stable disease accounts for 35%, and progressive disease accounts for 10%. The disease control rate is 90%. The average progression-free survival (PFS) time is 10.6 ± 2.8 months. The 6 months PFS rate is 62.5% and 12 months PFS rate is 32,5%. The rate of hematological toxicity was 7.5%, non-hematological toxicity was 37.5%, and immune-related toxicity was 10%. Common toxicities were grade 1 and 2
Article Details
Keywords
Non-small cell lung cancer (NSCLC), stage IV, imunotherapy, pembrolizumab
References
2. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019; 393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-7
3. Stage 4 Lung Cancer Prognosis: What to Expect. Healthline. March 22, 2019. Accessed May 26, 2024. https://www.healthline.com/ health/stage-4-lung-cancer-prognosis
4. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer. 2002;87(8): 825-833. doi:10.1038/sj.bjc. 6600540
5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37(7):537-546. doi:10.1200/JCO.18.00149